Ebola vaccine trial results are “extremely promising,” says WHOBMJ 2015; 351 doi: https://doi.org/10.1136/bmj.h4192 (Published 31 July 2015) Cite this as: BMJ 2015;351:h4192
- Zosia Kmietowicz
- 1The BMJ
Early results from a trial of a vaccine against Ebola virus disease being conducted in Guinea have been hailed as “an extremely promising development,” after they showed that none of the contacts of someone who had contracted the disease and who were vaccinated immediately became infected.
The trial of the rVSV-ZEBOV vaccine began on 7 March in the Basse Guinée region of Guinea, the only area in Guinea with new cases of Ebola virus disease at the start of the study on 1 April 2015. It used a ring vaccination strategy, the same approach used to eradicate smallpox in the 1970s, to target all contacts of newly infected patients for vaccination.
When a new case of Ebola virus disease was diagnosed, the researchers traced all people who may have been in close contact with the person with this …
Log in using your username and password
Log in through your institution
Register for a free trial to thebmj.com to receive unlimited access to all content on thebmj.com for 14 days.
Sign up for a free trial